

Liliana Montella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5457252/publications.pdf>

Version: 2024-02-01

47
papers

1,454
citations

361045

20
h-index

315357

38
g-index

49
all docs

49
docs citations

49
times ranked

1987
citing authors

#	ARTICLE	IF	CITATIONS
1	Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas. <i>Biomedicines</i> , 2022, 10, 150.	1.4	11
2	The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?. <i>Cancers</i> , 2022, 14, 774.	1.7	1
3	Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells. <i>Cancers</i> , 2021, 13, 2339.	1.7	4
4	Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions. <i>Cancers</i> , 2021, 13, 2359.	1.7	6
5	The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1909.	1.8	6
6	Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling. <i>Biomedicines</i> , 2021, 9, 1759.	1.4	1
7	Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study. <i>Chemotherapy</i> , 2019, 64, 48-56.	0.8	5
8	Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. <i>CNS Oncology</i> , 2019, 8, CNS32.	1.2	5
9	Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer. <i>Oncology</i> , 2018, 95, 353-359.	0.9	6
10	Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study. <i>Future Oncology</i> , 2017, 13, 415-423.	1.1	18
11	Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?. <i>World Journal of Gastroenterology</i> , 2016, 22, 6114.	1.4	27
12	Squamous cell carcinoma of the tongue in a female with advanced breast cancer: A case report of an elderly patient presenting with two types of cancer. <i>Oncology Letters</i> , 2014, 8, 235-237.	0.8	6
13	Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. <i>Future Oncology</i> , 2014, 10, 2141-2147.	1.1	30
14	Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series. <i>Oncology</i> , 2013, 84, 265-272.	0.9	27
15	Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1283-1288.	1.1	8
16	Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 603-609.	1.1	34
17	A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 102, 417-424.	1.4	60
18	Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1137-1143.	1.1	26

#	ARTICLE	IF	CITATIONS
19	Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 837-844.	1.1	73
20	Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. <i>Oncologist</i> , 2010, 15, 85-92.	1.9	162
21	Latest developments in targeted therapy for hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1635-1646.	1.1	8
22	Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance. <i>Journal of Clinical Oncology</i> , 2010, 28, 543-548.	0.8	142
23	Low-Dose Metronomic Oral Administration of Vinorelbine in the First-line Treatment of Elderly Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 301-306.	1.1	84
24	Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. <i>Journal of Bone and Mineral Metabolism</i> , 2009, 27, 110-113.	1.3	24
25	Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 7.	3.5	8
26	Somatostatin receptor expression in thymic tumors. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 3304.	3.0	7
27	Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women ≥65 years of age. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 285-292.	1.1	39
28	Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. <i>Supportive Care in Cancer</i> , 2008, 16, 209-214.	1.0	18
29	Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. <i>Cancer</i> , 2008, 113, 2524-2531.	2.0	88
30	Complementary Treatments in Thymic Neoplasms: Steroids and Octreotide. , 2008, , 241-246.		0
31	The Era of Targeted Therapies. <i>Archives of Dermatology</i> , 2007, 143, 788-9.	1.7	3
32	Atypical Cutaneous Lymphoid Hyperplasia Induced by Chemotherapy in a Patient with Advanced Colon Carcinoma. <i>Clinical Colorectal Cancer</i> , 2007, 6, 728-730.	1.0	4
33	Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life. <i>BMC Cancer</i> , 2007, 7, 18.	1.1	72
34	Cetuximab is an active treatment of metastatic and chemorefractory thymoma. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 757.	3.0	70
35	Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 34-39.	1.1	66
36	Thymoma followed by paroxysmal nocturnal hemoglobinuria: A unique clinical association in the context of multiorgan autoimmunity with a potential role for CD8+ T lymphocytes. <i>American Journal of Hematology</i> , 2006, 81, 774-778.	2.0	15

#	ARTICLE	IF	CITATIONS
37	Atrial fibrillation following chemotherapy for stage III diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease). <i>Annals of Hematology</i> , 2005, 84, 192-193.	0.8	18
38	Fatal Immunodeficiency in a Patient with Thymoma and Good's Syndrome. <i>Tumori</i> , 2005, 91, 361-363.	0.6	3
39	Conditions Suggesting Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3844-3846.	0.8	12
40	Fatal immunodeficiency in a patient with thymoma and Good's syndrome. <i>Tumori</i> , 2005, 91, 361-3.	0.6	3
41	Imatinib Mesylate for Cerebral Langerhans'-Cell Histiocytosis. <i>New England Journal of Medicine</i> , 2004, 351, 1034-1035.	13.9	45
42	Unusual Aspects of Melanoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 743-744.	0.8	1
43	Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin. <i>Experimental and Molecular Medicine</i> , 2004, 36, 268-273.	3.2	16
44	Clonal expansion of CD8+ BV8 T lymphocytes in bone marrow characterizes thymoma-associated B lymphopenia. <i>Blood</i> , 2003, 101, 3106-3108.	0.6	40
45	Ultra-Low-Dose Interleukin-2 in Unresectable Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 224-226.	0.6	27
46	Functional imaging of Langerhans cell histiocytosis by ¹¹¹ In-DTPA-D-Phe1-octreotide scintigraphy. <i>Cancer</i> , 2002, 94, 633-640.	2.0	17
47	Somatostatin analogs and prednisone in advanced refractory thymic tumors. <i>Cancer</i> , 2002, 94, 1414-1420.	2.0	104